Stella Maye Dilke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stella Maye Dilke has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Carolynne J. Vaizey
Department of Surgery & Cancer, Imperial Experimental Cancer Medicine Centre (ECMC), Imperial College London, ICTEM, Du Cane Road, London W12 0NN, UK
3 shared publications - Phil Tozer
Robin Phillips’ Fistula Research Unit, St Mark’s Hospital and Academic Institute, London, UK
3 shared publications - Kapil Sahnan
St Marks Hospital , London
2 shared publications - Adam T. Stearns
Sir Thomas Browne Academic Colorectal Unit Norfolk and Norwich University Hospital Trust Norwich UK
1 shared publication Ailsa L. Hart
St Mark's Hospital Harrow UK
1 shared publication- Alessandra Orlando
Sir Alan Parks Department of Physiology St Mark's Hospital, National Bowel Hospital London UK
1 shared publication
Latest Publications
- Open Access
Improving operative outcomes in patients with stomas
Stoma formation diverts the flow of faeces to an opening on the skin, away from a section of bowel. Stomas are used to reduce the risks of bowel surgery and their effects are thought to be temporary and benign. However, negative effects [e.g. diversion colitis (inflammation in the excluded segment), poor quality of life, and an unclear effect on homeostasis] occur. We investigated these changes and whether distal feeding (DF) – the introduction of nutrition directly into the defunctioned bowel prior to stoma reversal – could mitigate these effects. A series of clinical, qualitative, immunological, metabolomic and microbiomic experiments conducted across 133 patients identified consistent changes in immune and microbiome response which differed according to stoma formation and underlying disease process [colorectal cancer (CRC) with or without chemotherapy, intestinal failure (IF)], including a unique immune signature in circulating memory T-cell homing in stoma patients. DF induced the proliferation and altered homing of memory T cells, particularly in patients who had received chemotherapy. DF led to changes in serum metabolites, increased circulating markers of gut health (citrulline, serotonin), and modified the faecal microbiota. DF also promoted a faster return of bowel function and earlier hospital discharge in patients with CRC, while in IF it accelerated intestinal autonomy from parenteral nutrition. This in-depth analysis of sequential experiments characterises gut homeostasis and post-operative systemic immunity after stoma formation in CRC and IF patients, and quantifies and explains the benefit of DF in these groups. This research program has wide-ranging implications for patients worldwide with stomas. Given its simplicity, affordability and wide applicability, DF has the potential to become a transformative adjunct in surgical recovery and improved long-term gut health in patients with stomas.
Open AccessImproving operative outcomes in patients with stomas
Stoma formation diverts the flow of faeces to an opening on the skin, away from a section of bowel. Stomas are used to reduce the risks of bowel surgery and their effects are thought to be temporary and benign. However, negative effects [e.g. diversion colitis (inflammation in the excluded segment), poor quality of life, and an unclear effect on homeostasis] occur. We investigated these changes and whether distal feeding (DF) – the introduction of nutrition directly into the defunctioned bowel prior to stoma reversal – could mitigate these effects. A series of clinical, qualitative, immunological, metabolomic and microbiomic experiments conducted across 133 patients identified consistent changes in immune and microbiome response which differed according to stoma formation and underlying disease process [colorectal cancer (CRC) with or without chemotherapy, intestinal failure (IF)], including a unique immune signature in circulating memory T-cell homing in stoma patients. DF induced the proliferation and altered homing of memory T cells, particularly in patients who had received chemotherapy. DF led to changes in serum metabolites, increased circulating markers of gut health (citrulline, serotonin), and modified the faecal microbiota. DF also promoted a faster return of bowel function and earlier hospital discharge in patients with CRC, while in IF it accelerated intestinal autonomy from parenteral nutrition. This in-depth analysis of sequential experiments characterises gut homeostasis and post-operative systemic immunity after stoma formation in CRC and IF patients, and quantifies and explains the benefit of DF in these groups. This research program has wide-ranging implications for patients worldwide with stomas. Given its simplicity, affordability and wide applicability, DF has the potential to become a transformative adjunct in surgical recovery and improved long-term gut health in patients with stomas.
- Open Access
- 11 March 2025
- Published by Wiley in Colorectal Disease
- Vol. 27 (3) , e70050
Are women adequately informed about the use of instrumentation during vaginal delivery? A prospective review of the information on instrumental delivery provided to pregnant women and a retrospective review of the quality of consent for instrumental delivery
Aim: Instrumental delivery typically describes the use of ventouse or forceps to aid vaginal delivery. They are used in 10%–15% of all vaginal deliveries and in almost a third of all primiparous deliveries. They are associated with an increased risk of maternal and neonatal injury. Such maternal injuries may lead to significant functional problems such as faecal incontinence and these conditions can be life changing. Informed consent should be obtained before any medical procedure. This should be taken well before the procedure, documented clearly, and alternatives should be discussed. The aim of this study was to assess the information provided to pregnant women and the quality of consent obtained prior to instrumental vaginal delivery.Method: Patients were approached at 36 weeks’ gestation, prior to a planned vaginal delivery. The study was undertaken in the Obstetric Department of a busy District General Hospital in the UK. The patients’ understanding of labour, vaginal delivery and the use of instrumentation was assessed. Clinical notes of women who had an assisted vaginal delivery were reviewed to ascertain time of consent for use of instrumentation and amount of analgesia received at that point.Results: A total of 138 patients were included for prospective assessment. Only 4% were able to describe all stages of labour, 17% could describe some of the stages of labour and 78% were unable to describe any of the stages of labour. Eighty per cent of the participants were unaware that instrumentation may be used during delivery, 21% were aware that it may be used if necessary and only 2% were aware of the risk of maternal injury. Fifty‐nine case notes were reviewed. All had undergone either forceps or ventouse instrumentation. Eighteen per cent showed no record of informed consent. Sixty‐one per cent showed evidence of verbal consent and 20% had a signed consent in the clinical notes. All had been consented for use of instrumentation during the second stage of labour, often when opioid analgesia had been administered prior to consent.Conclusion: Knowledge about labour and the use of instrumentation during delivery appeared to be poor. The quality of consent taken for instrumental delivery appeared to be sub‐standard. Larger studies, done post the COVID‐19 epidemic, are needed to confirm that similar practices still occur in other hospitals and, if this is the case, urgent measures need to be taken to correct this.
- 11 March 2025
- Published by Wiley in Colorectal Disease
- Vol. 27 (3) , e70050
Open AccessAre women adequately informed about the use of instrumentation during vaginal delivery? A prospective review of the information on instrumental delivery provided to pregnant women and a retrospective review of the quality of consent for instrumental delivery
Aim: Instrumental delivery typically describes the use of ventouse or forceps to aid vaginal delivery. They are used in 10%–15% of all vaginal deliveries and in almost a third of all primiparous deliveries. They are associated with an increased risk of maternal and neonatal injury. Such maternal injuries may lead to significant functional problems such as faecal incontinence and these conditions can be life changing. Informed consent should be obtained before any medical procedure. This should be taken well before the procedure, documented clearly, and alternatives should be discussed. The aim of this study was to assess the information provided to pregnant women and the quality of consent obtained prior to instrumental vaginal delivery.Method: Patients were approached at 36 weeks’ gestation, prior to a planned vaginal delivery. The study was undertaken in the Obstetric Department of a busy District General Hospital in the UK. The patients’ understanding of labour, vaginal delivery and the use of instrumentation was assessed. Clinical notes of women who had an assisted vaginal delivery were reviewed to ascertain time of consent for use of instrumentation and amount of analgesia received at that point.Results: A total of 138 patients were included for prospective assessment. Only 4% were able to describe all stages of labour, 17% could describe some of the stages of labour and 78% were unable to describe any of the stages of labour. Eighty per cent of the participants were unaware that instrumentation may be used during delivery, 21% were aware that it may be used if necessary and only 2% were aware of the risk of maternal injury. Fifty‐nine case notes were reviewed. All had undergone either forceps or ventouse instrumentation. Eighteen per cent showed no record of informed consent. Sixty‐one per cent showed evidence of verbal consent and 20% had a signed consent in the clinical notes. All had been consented for use of instrumentation during the second stage of labour, often when opioid analgesia had been administered prior to consent.Conclusion: Knowledge about labour and the use of instrumentation during delivery appeared to be poor. The quality of consent taken for instrumental delivery appeared to be sub‐standard. Larger studies, done post the COVID‐19 epidemic, are needed to confirm that similar practices still occur in other hospitals and, if this is the case, urgent measures need to be taken to correct this.
- 8 October 2021
- Published by Wiley in Colorectal Disease
- Vol. 23 (12) , 3073-3089
Is fistulotomy with immediate sphincter reconstruction (FISR) a sphincter preserving procedure for high anal fistula? A systematic review and meta‐analysis
Aim: This systematic review aimed to assess the outcomes of fistulotomy or fistulectomy and immediate sphincter repair (FISR) in relation to healing, incontinence and sphincter dehiscence both overall and in patients with high anal fistulae.Methods: Medline, Embase and The Cochrane library were searched for studies of patients undergoing FISR for anal fistula. Data regarding healing, continence and sphincter dehiscence were extracted overall and for high anal fistulae. The DerSimonian‐Laird random‐effects method was used for pooled analysis, heterogeneity between studies was assessed based on the significance of between‐study heterogeneity, and on the size of the I2 value. Risk of bias was assessed using the Cochrane risk of bias tool and the Newcastle‐Ottawa scale.Results: We identified 21 studies evaluating 1700 patients. Pooled analysis of healing reached 93% (95% CI: 91%–95%, I2 = 51% p‐value for heterogeneity = 0.004), with continence disturbance and worsening continence reaching 11% (95% CI: 6%–18%, I2 = 87% p < 0.001) and 8% (95% CI: 4%–13%, I2 = 74% p < 0.001), respectively. Subgroup analysis according to fistula height could only be conducted on limited data. Pooled healing in high anal fistulae was 89% (95% CI: 84%–94%, I2 = 76% p < 0.001), 16% suffered disturbance of continence (95% CI: 7%–27%, I2 = 89% p < 0.001), 8% worsening continence from baseline (95% CI: 2%–16%, I2 = 80% p < 0.001) and 2% suffered sphincter dehiscence (95% CI: 0%–10%, I2 = 89% p < 0.001).Conclusion: The evidence suggests FISR is a safe, effective procedure. However, data are limited by inconsistencies in reporting of continence and definition of fistula height, particularly high anal fistulae. Significant heterogeneity means that outcomes in high fistulae remain uncertain.
- 8 October 2021
- Published by Wiley in Colorectal Disease
- Vol. 23 (12) , 3073-3089
Is fistulotomy with immediate sphincter reconstruction (FISR) a sphincter preserving procedure for high anal fistula? A systematic review and meta‐analysis
Aim: This systematic review aimed to assess the outcomes of fistulotomy or fistulectomy and immediate sphincter repair (FISR) in relation to healing, incontinence and sphincter dehiscence both overall and in patients with high anal fistulae.Methods: Medline, Embase and The Cochrane library were searched for studies of patients undergoing FISR for anal fistula. Data regarding healing, continence and sphincter dehiscence were extracted overall and for high anal fistulae. The DerSimonian‐Laird random‐effects method was used for pooled analysis, heterogeneity between studies was assessed based on the significance of between‐study heterogeneity, and on the size of the I2 value. Risk of bias was assessed using the Cochrane risk of bias tool and the Newcastle‐Ottawa scale.Results: We identified 21 studies evaluating 1700 patients. Pooled analysis of healing reached 93% (95% CI: 91%–95%, I2 = 51% p‐value for heterogeneity = 0.004), with continence disturbance and worsening continence reaching 11% (95% CI: 6%–18%, I2 = 87% p < 0.001) and 8% (95% CI: 4%–13%, I2 = 74% p < 0.001), respectively. Subgroup analysis according to fistula height could only be conducted on limited data. Pooled healing in high anal fistulae was 89% (95% CI: 84%–94%, I2 = 76% p < 0.001), 16% suffered disturbance of continence (95% CI: 7%–27%, I2 = 89% p < 0.001), 8% worsening continence from baseline (95% CI: 2%–16%, I2 = 80% p < 0.001) and 2% suffered sphincter dehiscence (95% CI: 0%–10%, I2 = 89% p < 0.001).Conclusion: The evidence suggests FISR is a safe, effective procedure. However, data are limited by inconsistencies in reporting of continence and definition of fistula height, particularly high anal fistulae. Significant heterogeneity means that outcomes in high fistulae remain uncertain.
- 21 May 2021
- Published by Wiley in Colorectal Disease
- Vol. 23 (8) , 2091-2099
Prognostic factors associated with unhealed perineal wounds post‐proctectomy for perianal Crohn's disease: a two‐centre study
Aim: The aim of this work was to determine the factors associated with poor wound healing in patients with perianal Crohn's disease (pCD) who had undergone proctectomy in the era of biologic therapies.Method: Case record review was performed on 103 patients with pCD who underwent proctectomy at St Mark's Hospital, Harrow and the Western General Hospital, Edinburgh between 2005 and 2017. Healing rates at 6 and 12 months post‐proctectomy were considered; univariate analysis was performed.Results: Sixty out of 103 patients (58.3%) had failure of wound healing at 6 months and 41/103 (39.8%) at 12 months. In total, 63.1% (65/103) patients received biologic therapies prior to proctectomy; however, exposure to biologics was not a significant factor in predicting failure of wound healing at 12 months (infliximab p = 0.255; adalimumab p = 0.889; vedolizumab p = 0.153). Male gender was the only variable associated with poor wound healing at 12 months on univariate analysis (p = 0.017). A lower pre‐operative C‐reactive protein was associated with early wound healing at 6 months compared with at 12 months (p = 0.041) on univariate analysis. Other parameters not associated with rates of wound healing included smoking status, corticosteroid exposure, thiopurine exposure, number of previous biologics, perianal sepsis on MRI within the last 12 months, duration of CD prior to proctectomy and pre‐operative albumin.Conclusion: More than a third of patients had unhealed wounds 12 months after proctectomy. We report that unhealed wounds are more common in male patients. Importantly, our results also suggest that exposure to biologics does not affect rates of wound healing.
- 21 May 2021
- Published by Wiley in Colorectal Disease
- Vol. 23 (8) , 2091-2099
Prognostic factors associated with unhealed perineal wounds post‐proctectomy for perianal Crohn's disease: a two‐centre study
Aim: The aim of this work was to determine the factors associated with poor wound healing in patients with perianal Crohn's disease (pCD) who had undergone proctectomy in the era of biologic therapies.Method: Case record review was performed on 103 patients with pCD who underwent proctectomy at St Mark's Hospital, Harrow and the Western General Hospital, Edinburgh between 2005 and 2017. Healing rates at 6 and 12 months post‐proctectomy were considered; univariate analysis was performed.Results: Sixty out of 103 patients (58.3%) had failure of wound healing at 6 months and 41/103 (39.8%) at 12 months. In total, 63.1% (65/103) patients received biologic therapies prior to proctectomy; however, exposure to biologics was not a significant factor in predicting failure of wound healing at 12 months (infliximab p = 0.255; adalimumab p = 0.889; vedolizumab p = 0.153). Male gender was the only variable associated with poor wound healing at 12 months on univariate analysis (p = 0.017). A lower pre‐operative C‐reactive protein was associated with early wound healing at 6 months compared with at 12 months (p = 0.041) on univariate analysis. Other parameters not associated with rates of wound healing included smoking status, corticosteroid exposure, thiopurine exposure, number of previous biologics, perianal sepsis on MRI within the last 12 months, duration of CD prior to proctectomy and pre‐operative albumin.Conclusion: More than a third of patients had unhealed wounds 12 months after proctectomy. We report that unhealed wounds are more common in male patients. Importantly, our results also suggest that exposure to biologics does not affect rates of wound healing.
- Open Access
- 18 September 2020
- Published by Hindawi Limited in GastroHep
- Vol. 2 (6) , 266-271
Diversion colitis: Aetiology, diagnosis and treatment. A systematic review
Background Diversion colitis (DC) is an inflammatory disease associated with diversion of the bowel following operative intervention and formation of ostomy. DC has an association with inflammatory bowel disease (IBD) but is also seen after diversion for rectal cancer, mesenteric ischaemia and trauma. Symptoms include rectal discharge, rectal bleeding and abdominal pain. This article reviews papers concerning treatment, aetiology and diagnosis of DC. Methods A systematic search of the online databases MEDLINE and EMBASE were included between 1969 ‐ October 2018. A total of 4898 abstracts and 71 full‐text articles were screened with 18 papers included (n = 578). Randomised controlled trials, cohort studies and observational studies investigating the diagnosis, treatment or aetiology of DC were included. Results Three studies investigated treatments for DC. Of these, colonic irrigation with a fibre solution and twice daily butyrate enemas demonstrated a significant reduction in the endoscopic score of inflammation in the diverted bowel (p=0.01 and p=0.0083 respectively). Several aetiologies for DC were suggested, including an aerobic microbial dysbiosis. One study suggested that a reduction in Bifidobacterium species was associated with reduced severity of DC (p= 0.005). It was not clear how duration of defunctioning related to incidence of DC. Conclusion Whilst there are endoscopic and microscopic changes in the small bowel and colon associated with diversion, a sequence of events leading to the development of DC has not been elucidated. The most striking weakness with these studies was the lack of significant follow‐up and heterogeneity. Larger longitudinal studies would be of benefit.
- 18 September 2020
- Published by Hindawi Limited in GastroHep
- Vol. 2 (6) , 266-271
Open AccessDiversion colitis: Aetiology, diagnosis and treatment. A systematic review
Background Diversion colitis (DC) is an inflammatory disease associated with diversion of the bowel following operative intervention and formation of ostomy. DC has an association with inflammatory bowel disease (IBD) but is also seen after diversion for rectal cancer, mesenteric ischaemia and trauma. Symptoms include rectal discharge, rectal bleeding and abdominal pain. This article reviews papers concerning treatment, aetiology and diagnosis of DC. Methods A systematic search of the online databases MEDLINE and EMBASE were included between 1969 ‐ October 2018. A total of 4898 abstracts and 71 full‐text articles were screened with 18 papers included (n = 578). Randomised controlled trials, cohort studies and observational studies investigating the diagnosis, treatment or aetiology of DC were included. Results Three studies investigated treatments for DC. Of these, colonic irrigation with a fibre solution and twice daily butyrate enemas demonstrated a significant reduction in the endoscopic score of inflammation in the diverted bowel (p=0.01 and p=0.0083 respectively). Several aetiologies for DC were suggested, including an aerobic microbial dysbiosis. One study suggested that a reduction in Bifidobacterium species was associated with reduced severity of DC (p= 0.005). It was not clear how duration of defunctioning related to incidence of DC. Conclusion Whilst there are endoscopic and microscopic changes in the small bowel and colon associated with diversion, a sequence of events leading to the development of DC has not been elucidated. The most striking weakness with these studies was the lack of significant follow‐up and heterogeneity. Larger longitudinal studies would be of benefit.
- Open Access
- 18 August 2020
- Published by BMJ in Frontline Gastroenterology
- Vol. 12 (7) , 677-682
Distal feeding–bowel stimulation to treat short-term or long-term pathology: a systematic review
Background Distal feeding (DF) describes the insertion of a feeding tube into a fistula or stoma to administer a liquid feed into the distal bowel. It is currently used clinically in patients who are unable to absorb enough nutrition orally. This systematic review investigates DF as a therapeutic measure across a spectrum of patients with stomas and fistulae. Methods A total of 2825 abstracts and 44 full-text articles were screened via OVID. Fifteen papers were included for analysis. Randomised controlled trials, cohort and observational studies investigating DF as a therapeutic measure were included. Results Three feeds were used across the studies—reinfusion of effluent, infusion of prebiotic or a mixture. The studies varied the length of feeding between 24 hours and 61 days, and the mode of feeding, bolus or continuous varied. DF was demonstrated to effectively wean patients from parenteral nutrition in two papers. Two papers demonstrated a significant reduction in stoma output. Three papers demonstrated improved postoperative complication rates with distal feeding regimens, including ileus (2.85% vs 20% in unfed population, p=0.024). One paper demonstrated a reduction in postoperative stool frequency. Conclusions This review was limited by study heterogeneity and the lack of trial data, and in the patient groups involved, the variability in diet and length of regimen. These studies suggest that DF can significantly reduce stoma output and improve renal and liver function; however, the mechanism is not clear. Further mechanistic work on the immunological and microbiological action of DF would be important.
- 18 August 2020
- Published by BMJ in Frontline Gastroenterology
- Vol. 12 (7) , 677-682
Open AccessDistal feeding–bowel stimulation to treat short-term or long-term pathology: a systematic review
Background Distal feeding (DF) describes the insertion of a feeding tube into a fistula or stoma to administer a liquid feed into the distal bowel. It is currently used clinically in patients who are unable to absorb enough nutrition orally. This systematic review investigates DF as a therapeutic measure across a spectrum of patients with stomas and fistulae. Methods A total of 2825 abstracts and 44 full-text articles were screened via OVID. Fifteen papers were included for analysis. Randomised controlled trials, cohort and observational studies investigating DF as a therapeutic measure were included. Results Three feeds were used across the studies—reinfusion of effluent, infusion of prebiotic or a mixture. The studies varied the length of feeding between 24 hours and 61 days, and the mode of feeding, bolus or continuous varied. DF was demonstrated to effectively wean patients from parenteral nutrition in two papers. Two papers demonstrated a significant reduction in stoma output. Three papers demonstrated improved postoperative complication rates with distal feeding regimens, including ileus (2.85% vs 20% in unfed population, p=0.024). One paper demonstrated a reduction in postoperative stool frequency. Conclusions This review was limited by study heterogeneity and the lack of trial data, and in the patient groups involved, the variability in diet and length of regimen. These studies suggest that DF can significantly reduce stoma output and improve renal and liver function; however, the mechanism is not clear. Further mechanistic work on the immunological and microbiological action of DF would be important.